4 news items
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
ASND
15 May 24
.
The company said adults with hypoparathyroidism in the United States, who are receiving TransCon PTH in clinical trials and Expanded Access Program
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
ASND
14 May 24
are receiving TransCon PTH in our clinical trials and our Expanded Access Program (EAP) will continue to receive their medication, and the EAP
Ascendis Pharma Reports First Quarter 2024 Financial Results
ASND
2 May 24
. Those who would like to participate may access the live webcast
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
ASND
25 Apr 24
2024 financial results. Those who would like to participate may access the live webcast
- Prev
- 1
- Next